| Mechanosensing is critical for axon growth in the developing brain DE Koser, AJ Thompson, SK Foster, A Dwivedy, EK Pillai, GK Sheridan, ... Nature neuroscience 19 (12), 1592-1598, 2016 | 574 | 2016 |
| Trial of prasinezumab in early-stage Parkinson’s disease G Pagano, KI Taylor, J Anzures-Cabrera, M Marchesi, T Simuni, K Marek, ... New England Journal of Medicine 387 (5), 421-432, 2022 | 171 | 2022 |
| Histone deacetylases control neurogenesis in embryonic brain by inhibition of BMP2/4 signaling M Shakèd, K Weissmüller, H Svoboda, P Hortschansky, N Nishino, ... PloS one 3 (7), e2668, 2008 | 81 | 2008 |
| RNA-binding protein Hermes/RBPMS inversely affects synapse density and axon arbor formation in retinal ganglion cells in vivo H Hörnberg, F Wollerton-van Horck, D Maurus, M Zwart, H Svoboda, ... Journal of Neuroscience 33 (25), 10384-10395, 2013 | 63 | 2013 |
| A phase II study to evaluate the safety and efficacy of prasinezumab in early Parkinson's disease (PASADENA): rationale, design, and baseline data G Pagano, FG Boess, KI Taylor, B Ricci, B Mollenhauer, W Poewe, ... Frontiers in neurology 12, 705407, 2021 | 50 | 2021 |
| Reliability and validity of the Roche PD Mobile Application for remote monitoring of early Parkinson’s disease F Lipsmeier, KI Taylor, RB Postuma, E Volkova-Volkmar, T Kilchenmann, ... Scientific reports 12 (1), 12081, 2022 | 36 | 2022 |
| Effects of cyclosporine A and its immunosuppressive or non-immunosuppressive derivatives [D-Ser] 8-CsA and Cs9 on mitochondria from different brain regions ZZ Gizatullina, TM Gaynutdinov, H Svoboda, D Jerzembek, A Knabe, ... Mitochondrion 11 (3), 421-429, 2011 | 15 | 2011 |
| PASADENA: A Phase 2 study to evaluate the safety and efficacy of prasinezumab in early Parkinson's disease; Part 1 Week-52 results G Pagano, K Taylor, J Cabrera, M Marchesi, W Zago, R Tripuraneni, ... MOVEMENT DISORDERS 35, S410-+, 2020 | 8 | 2020 |
| L. da, F. Costa, J. Guck, CE Holt and K. Franze DE Koser, AJ Thompson, SK Foster, A Dwivedy, EK Pillai, GK Sheridan, ... Nat. Neurosci 19, 1592-1598, 2016 | 8 | 2016 |
| Prasinezumab reduced progression of Parkinson’s disease motor features measured by Roche PD Mobile Application v2 sensor features: PASADENA Phase II Part 1 K Taylor, F Lipsmeier, E Volkova-Volkmar, D Rukina, J Anzures Cabrera, ... Mov Disord 36 (Suppl. 1), 2021 | 3 | 2021 |
| PASADENA open-label extension: results after an additional year of treatment with prasinezumab G Pagano, A Reyes, A Monnet, M Martinec, N Shariati, T Simuni, K Marek, ... Int. Congr. Park. Dis. Mov. Disord. Cph., Den., 27-31, 2023 | 1 | 2023 |
| Remote identification of early, sensor-based markers of Parkinson's Disease using participants’ smartphones: The Parkinson Progression Marker Initiative Digital sub-study W Popp, K Taylor, T Perumal, C Tanner, A Siderowf, L Chahine, E Brown, ... Movement Disorders 37, S347-S347, 2022 | 1 | 2022 |
| 053 Brainshuttle AD: Investigating safety, tolerability, and PK/PD of RG6102 in prodromal/mild-to-moderate AD L Kulic, A Vogt, F Alcaraz, P Barrington, M Marchesi, G Klein, R Croney, ... Journal of Neurology, Neurosurgery & Psychiatry 93 (9), e2, 2022 | 1 | 2022 |
| Remote monitoring of progression in early Parkinson’s disease: reliability and validity of the Roche PD Mobile Application v2 F Lipsmeier, KI Taylor, RB Postuma, E Volkova-Volkmar, T Kilchenmann, ... medRxiv, 2021.10. 07.21264414, 2021 | 1 | 2021 |
| Phase II PASADENA Part one Week 52 results: Evaluating safety and efficacy of prasinezumab in early Parkinson's disease G Pagano, K Taylor, J Anzures-Cabrera, W Zago, R Tripuraneni, ... | 1 | 2021 |
| Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson’s disease G Pagano, KI Taylor, J Anzures Cabrera, T Simuni, K Marek, RB Postuma, ... Nature Medicine, 1-8, 2024 | | 2024 |
| Exploratory Analysis of PASADENA Open-label Extension Evaluating the Effect of Prasinezumab on the Progression of Motor Signs and Symptoms (S30. 006) G Pagano, A Monnet, A Reyes, T Simuni, R Postuma, N Pavese, F Stocchi, ... Neurology 102 (17_supplement_1), 5152, 2024 | | 2024 |
| Sustained effect of prasinezumab on Parkinson’s disease motor progression in the open-label extension of the PASADENA trial G Pagano, A Monnet, A Reyes, B Ribba, H Svoboda, T Kustermann, ... | | 2024 |
| Exploratory Sensor-based Outcome Measures Show Divergent Slopes of Motor Sign Progression in Parkinson’s Disease Patients Treated with Prasinezumab K Taylor, F Lipsmeier, M Scelsi, E Volkova-Volkmar, D Rukina, W Popp, ... | | 2024 |
| Exploratory Delayed-Start Analysis Of PASADENA Part 3 52-Week OLE Evaluating Prasinezumab Efficacy On Motor Progression And Complications In Early-Stage PD (S32. 005) G Pagano, S Zanigni, A Monnet, K Taylor, A Hahn, T Simuni, K Marek, ... Neurology 100 (17 Supplement 2), 2023 | | 2023 |
Gennaro PaganoExpert Medical Director & Group Leader in Early Development @ RocheVerified email at roche.com
